denotes an abstract that is clinically relevant.
denotes that this is a ticketed session.
Description:
Since the 1970s, treatment with an anthracycline and cytarabine in the “3+7” fashion has been a cornerstone of curative-intent therapy for adult Acute Myeloid Leukemia (AML), but outcomes have remained unsatisfactory in many patients. This session will focus on recent attempts using small molecule inhibitors, antigen-specific immunotherapies, and cellular therapies--most importantly allogeneic hematopoietic cell transplantation--to improve on the results obtained with 3+7 based treatment.
Dr. Eytan Stein will review how discoveries of somatic mutations in AML have led to the development of targeted therapies against specific mutant proteins that are thought to be oncogenic drivers of disease. He will then describe how these targeted therapies may be integrated into the treatment of AML over the next five years.
Dr. Roland Walter will review the results obtained thus far with unconjugated and conjugated antibodies as well as passive and active immunotherapies for patients with AML. He will then provide an outlook of the many evolving antigen-specific treatment strategies for this disease.
Dr. Marcos de Lima will discuss recent developments in preparative regimen and allogeneic graft engineering, and review post-transplant interventions aimed at decreasing AML relapse rates after allogeneic transplantation.